Medical University of South Carolina researchers have secured up to $5 million in funding expected over six years from the National Institute on Drug Abuse to address the complex links between opioid use disorder (OUD), intimate partner violence and post-traumatic stress disorder. They are developing a digital toolkit to identify these intertwined risk factors early with the goal of improving OUD treatment outcomes.

Nearly three dozen Binghamton University researchers have been honored for their work by a Stanford University study that looks at the impact of scientists worldwide.

A groundbreaking study from Emory University demonstrates how psilocybin-assisted therapy could impact more than 5 million people in the U.S. pending approval from the FDA. The findings highlight both the national need for therapies featuring psilocybin, the active ingredient in hallucinogenic mushrooms, as well as the considerations that elected officials, insurance companies, and public health agencies would need to be aware of to successfully roll-out access to psilocybin-assisted therapy (PSIL-AT). 

The new Contact Allergen Management Program (CAMP) 2.0, from the American Contact Dermatitis Society (ACDS), is a web- and app-based resource designed to help patients manage allergic contact dermatitis.